Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Clinical & Experimental OncologyISSN: 2324-9110
Nandini Hayes Author
Subjects of specialization
Affiliation
Colorectal cancer, Cancer chemotherapy, Prostate biomarker, Endometrial cancer
Institute of Health Sciences Education, Barts and the London School of Medicine and Dentistry Queen Mary University of London, United Kingdom
Biography
Nandini Hayes was working in the Institute of Health Sciences Education, Barts and the London School of Medicine and Dentistry Queen Mary University of London, United Kingdom.
Publications
Research Article Subscription
Trastuzumab Resistance: What Are We Offering to Breast Cancer Patients?
Author(s): Sonel Patel, Nandini Hayes and Maria Teresa Esposito
Human epidermal growth factor receptor-2 (HER2/ErbB-2) is a receptor tyrosine kinase involved in cell growth and differentiation and over-expressed in about 15-30% of breast cancers. Trastuzumab is an anti-HER2 monoclonal antibody that has significantly improved survival of patients with early and metastatic breast cancer (BC). However, 65% patients experience primary and secondary resistance. This article explores existing and emerging combination therapy for HER2 positive breast cancer, highlighting the success of trastuzumab in combination with another monoclonal antibody, pertuzumab and small molecule tyrosine kinase inhibitors lapatinib and neratinib. Recent studies have indicated that combination of trastuzumab, pertuzumab and lapatinib increases the 3-year overall survival from 9... view more»
Google Scholars / Researchers Sites
